C5 and COVID-19: In a high inflammatory state, as can be seen in severely ill HSCT recipients with TA‐TMA or COVID‐19 patients, there is an acute phase response of the liver with massive C5 production and additional C5 production by activated circulating inflammatory cells and injured endothelial cells.